Synthesis and Antitumor Activity of Innovative Homotriazine Compounds

doi:10.6023/cjoc202408021

Abstract

Employing the principle of active moiety concatenation, a novel series of symmetrical triazine compounds were designed. A series of novel triazine compounds were synthesized using cyanuric chloride, amines, and chalcones as the initial reactants. The structures of these compounds were characterized through FT-IR, ¹H-NMR, ¹³C-NMR, high-resolution mass spectrometry (HRMS) and high performance liquid chromatography (HPLC). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetra- zolium bromide (MTT) assay was employed to evaluate the in vitro anti-proliferative activity of the new s-triazine compounds against human lung cancer cells (A549), human cervical cancer cells (HeLa), human breast cancer cells (MCF-7) and human colon cancer cells (SW620). The findings indicated that several compounds exhibited promising antitumor effects. Notably, (E)-1-(4-((4,6-dimorpholino-1,3,5-triazin-2-yl)oxy)phenyl)-3-(thiophen-2-yl)prop-2-en-1-one (3bg) demonstrated efficacy as a broad-spectrum anticancer agent, exhibiting significant activity against the A549, HeLa, and MCF-7 cell lines. Furthermore, (E)-1-(4-((4,6-dimorpholino-1,3,5-triazin-2-yl)oxy)phenyl)-3-phenylprop-2-en-1-one (3bb) displayed the most potent in vitro antitumor activity against the MCF-7 cell line with an IC₅₀ value of 16.4 μmol/L, establishing it as the most active compound in assay.

Key words: s-triazine compounds, α,β-unsaturated ketones, antitumor activity

Cite this article

Tiantian He, Lijiao Sun, Jiahui Lü, Jinjing Li, Yonghong Du. Synthesis and Antitumor Activity of Innovative Homotriazine Compounds[J]. Chinese Journal of Organic Chemistry, 2025, 45(7): 2577-2585.

Export EndNote|Reference Manager|ProCite|BibTeX|RefWorks

share this article

Fig. & Tab. 6

References 26

[4]	Gunasekaran P.; Rajasekaran G.; Han E. H.; Chung Y.-H.; Choi Y.-J.; Yang Y. J.; Lee J. E.; Kim H. N.; Lee K.; Kim J.-S.; Lee H. J.; Choi E.-J.; Kim E.-K.; Shin S. Y.; Bang J. K. Sci. Rep. 2019, 9, 1292. doi: 10.1038/s41598-018-37785-z pmid: 30718691
[5]	Wang K.; Yang H.; Liao Z.; Li S.; Hambsch M.; Fu G.; Manns- feld S. C. B.; Sun Q.; Zhang T. J. Am. Chem. Soc. 2023, 145, 5203.
[6]	Lee C. H.; Yamamoto T. Tetrahedron Lett. 2001, 42, 3993.
[7]	Chauhan D. S.; Quraishi M. A.; Nik W. B. W.; Srivastava V. J. Mol. Liq. 2021, 321, 114747.
[8]	Chen H.; Gu Y.; Yuan X.; Zhao L.; Zhao J.; Qin Z.; Liu L.; Li X.; Cao K.; Zhang J. Chin. J. Org. Chem. 2011, 31, 1266 (in Chinese).
	( 陈华, 谷云景, 苑香果, 赵莲, 赵建鹏, 秦占斌, 刘丽, 李小六, 曹克强, 张金超, 有机化学, 2011, 31, 1266.)
[9]	Zhang J.; Zhou P.; Xiao D.; Liu W. Chin. J. Org. Chem. 2021, 41, 4154 (in Chinese).
	( 张建涛, 周鹏, 肖朵朵, 刘卫兵, 有机化学, 2021, 41, 4154.) doi: 10.6023/cjoc202107023
[10]	Gao H. D.; Liu P.; Yang Y.; Gao F. RSC Adv. 2016, 6, 83438.
[11]	Sakakibara N.; Balboni G.; Congiu C.; Onnis V.; Demizu Y.; Misawa T.; Kurihara M.; Kato Y.; Maruyama T.; Toyama M.; Okamoto M.; Baba M. Antiviral Chem. Chemother. 2015, 24, 62.
[12]	Baréa P.; Barbosa V. A.; Bidóia D. L.; Paula J. C.; Stefanello T. F.; Costa W. F.; Nakamura C. V.; Sarragiotto M. H. Eur. J. Med. Chem. 2018, 150, 579. doi: S0223-5234(18)30249-6 pmid: 29549842
[13]	Patel A. B.; Chikhalia K. H.; Kumari P. Eur. J. Med. Chem. 2014, 79, 57. doi: 10.1016/j.ejmech.2014.03.085 pmid: 24721315
[14]	Shandilya A.; Hoda N.; Khan S.; Jameel E.; Kumar J.; Jayaram B. J. Mol. Graphics Modell. 2017, 71, 96.
[15]	Masih A.; Agnihotri A. K.; Srivastava J. K.; Pandey N.; Bhat H. R.; Singh U. P. J. Biochem. Mol. Toxicol. 2021, 35, e22659.
[16]	Velihina E. S.; Obernikhina N. V.; Pilyo S. G.; Kachkovsky O. D.; Brovarets V. S. J. Biochem. Mol. Toxicol. 2021, 25, 1441.
[17]	Makowska A.; Sączewski F.; Bednarski P. J.; Sączewski J.; Balewski Ł. Molecules 2018, 23, 1616.
[18]	Chalermnon M.; Cherdchom S.; Sereemaspun A.; Rojanathanes R.; Khotavivattana T. Molecules 2021, 26, 1028.
[19]	Zacharie B.; Abbott S. D.; Duceppe J. S.; Gagnon D. L.; Grouix D. B.; Geerts L.; Gervais L.; Sarra-Bournet F.; Perron V.; Wilb N.; Penney C. L.; Laurin P. ChemistryOpen 2018, 7, 737. doi: 10.1002/open.201800136 pmid: 30258746
[20]	Rubab L.; Afroz S.; Ahmad S.; Hussain S.; Nawaz I.; Irfan A.; Batool F.; Kotwica-Mojzych K.; Mojzych M. Molecules 2022, 27, 1604.
[21]	Karpavičienė I.; Valiulienė G.; Raškevičius V.; Lebedytė I.; Brukštus A.; Kairys V.; Navakauskienė R.; Čikotienė I. Eur. J. Med. Chem. 2015, 98, 30. doi: 10.1016/j.ejmech.2015.05.012 pmid: 26005022
[22]	Jung J. I.; Lim S. S.; Choi H. J.; Cho H. J.; Shin H. K.; Kim E. J.; Chung W. Y.; Park K. K.; Park J. H. Y. J. Nutr. Biochem. 2006, 17, 689. doi: 10.1016/j.jnutbio.2005.11.006 pmid: 16517140
[1]	Siegel R. L.; Miller K. D.; Fuchs H. E.; Jemal A. Ca-Cancer J. Clin. 2022, 72, 524.
[2]	Santos B. A. M. C.; da Silva A. C. P.; Bello M. L.; Goncalves A. S.; Gouvea T. A.; Rodrigues R. F.; Cabral L. M.; Rodrigues C. R. J. Photochem. Photobiol., A 2018, 356, 219.
[3]	Hussain M.; Khan K. M.; Ali S. I.; Parveen R.; Shim W. S. Fiber Polym. 2009, 10, 407.
[23]	Yun J. M.; Kweon M. H.; Kwon H.; Hwang J. K.; Mukhtar H. Carcinogenesis 2006, 27, 1454.
[24]	Nozaki H.; Hayashi K. I.; Kido M.; Kakumoto K.; Ikeda S.; Matsuura N.; Tani H.; Takaoka D.; Iinuma M.; Akao Y. Tetrahedron Lett. 2007, 48, 8290.
[25]	Szliszka E.; Czuba Z. P.; Mazur B.; Paradysz A.; Krol W. Molecules 2010, 15, 5336. doi: 10.3390/molecules15085336 pmid: 20714300
[26]	Orlikova B.; Schnekenburger M.; Zloh M.; Golais F.; Diederich M.; Tasdemir D. Oncol. Rep. 2012, 28, 797. doi: 10.3892/or.2012.1870 pmid: 22710558

Compound	IC₅₀/(μmol•L^－1)
Compound	A549	Hela	MCF-7	SW620
Cisplatin	8.9±0.42	6.2±1.12	14.3±2.22	18.6±1.35
3aa	35.4±0.51	120.3±1.39	81.8±1.79	26.8±6.92
3ab	20.8±0.52	15.6±1.39	30.5±4.38	94.5±0.50
3ac	41.3±0.77	92.6±0.64	75.1±2.40	42.7±2.11
3ad	100.8±1.54	71.4±4.00	60.5±2.35	69.9±2.77
3ae	18.5±0.58	26.3±1.14	33.7±7.84	41.4±2.80
3af	88.6±1.84	51.2±6.22	66.8±1.74	36.6±0.76
3bb	28.6±1.34	42.2±0.45	16.4±3.22	45.5±1.12
3bc	39.4±5.05	45.9±1.22	25.7±2.27	40.6±0.45
3bd	68.6±0.59	72.3±2.15	46.5±0.57	77.8±0.90
3be	12.8±5.60	16.9±1.05	35.6±4.27	40.8±0.79
3bf	26.8±1.57	69.3±0.95	70.5±1.84	47.7±0.92
3bg	19.6±0.44	18.2±12.63	19.6±2.98	53.3±18.74
3ca	90.6±36.70	77.3±0.88	72.6±3.00	81.1±9.16
3cb	46.6±0.31	56.6±0.10	61.7±2.78	43.8±4.82
3cc	91.6±3.93	75.5±10.18	42.6±0.22	83.6±2.45
3cd	69.6±7.01	77.4±11.34	92.5±23.97	81.3±7.72
3ce	41.5±0.52	56.8±1.09	67.6±4.87	48.3±4.53
3cf	88.2±35.98	94.3±4.93	105.3±46.64	115.4±22.42

Compound	IC₅₀/(μmol•L^－1)
Compound	A549	Hela	MCF-7	SW620
Cisplatin	8.9±0.42	6.2±1.12	14.3±2.22	18.6±1.35
3aa	35.4±0.51	120.3±1.39	81.8±1.79	26.8±6.92
3ab	20.8±0.52	15.6±1.39	30.5±4.38	94.5±0.50
3ac	41.3±0.77	92.6±0.64	75.1±2.40	42.7±2.11
3ad	100.8±1.54	71.4±4.00	60.5±2.35	69.9±2.77
3ae	18.5±0.58	26.3±1.14	33.7±7.84	41.4±2.80
3af	88.6±1.84	51.2±6.22	66.8±1.74	36.6±0.76
3bb	28.6±1.34	42.2±0.45	16.4±3.22	45.5±1.12
3bc	39.4±5.05	45.9±1.22	25.7±2.27	40.6±0.45
3bd	68.6±0.59	72.3±2.15	46.5±0.57	77.8±0.90
3be	12.8±5.60	16.9±1.05	35.6±4.27	40.8±0.79
3bf	26.8±1.57	69.3±0.95	70.5±1.84	47.7±0.92
3bg	19.6±0.44	18.2±12.63	19.6±2.98	53.3±18.74
3ca	90.6±36.70	77.3±0.88	72.6±3.00	81.1±9.16
3cb	46.6±0.31	56.6±0.10	61.7±2.78	43.8±4.82
3cc	91.6±3.93	75.5±10.18	42.6±0.22	83.6±2.45
3cd	69.6±7.01	77.4±11.34	92.5±23.97	81.3±7.72
3ce	41.5±0.52	56.8±1.09	67.6±4.87	48.3±4.53
3cf	88.2±35.98	94.3±4.93	105.3±46.64	115.4±22.42

新型均三嗪化合物的合成及抗肿瘤活性